HeidelbergCapital is an independent Private Equity Funds Group, specialising in Secondary Direct Investments, e.g. the acquisition of shareholdings in companies previously held by private equity/venture capital funds or banks.

News

20.11.2017


Nanogate
SE Intends to Continue its Course of Expansion With Further Acquisition and to Extend its Global Market Position

06.11.2017


4SC:
First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma

10.10.2017


4SC:
Resminostat demonstrates potential to significantly alleviate itching in CTCL patients

28.09.2017


Nanogate
SE improves its margin in the first half of the year and expects sales of over EUR 250 million over the medium term

13.09.2017


4SC:
Phase I study of 4SC’s resminostat indicates efficacy in biliary tract cancer

04.02.2016


Nanogate
driving international growth forward – Strong foreign business expected for 2016

About us


HeidelbergCapital was founded mid 2007. The company is jointly managed by Dr. Clemens Doppler and Prof. Dr. Martin Weiblen, former Managing Director of a multi-billion family office in London/U.K. and advisor to several Life Science-Funds. Dr. Clemens Doppler is a former Partner at 3i, the British Private Equity Group. The New York based Private Equity Investor Auda has committed c150m USD for the first fund, HeidelbergCapital Private Equity Fund I.

The portfolio of HeidelbergCapital ranges from investments in later stage venture companies with a proven business model to established mid-size operations. As an active partner, HeidelbergCapital supports the companies in strategic business decisions, but also provides, where appropriate, funding for further growth.

Investments

4sc – Martinsried (D)

Drug development company

MerLion – Singapur

Drug development company

Nanogate – Saarbrücken (D)

High performance surfaces

Vasopharm – Würzburg (D)

Drug development company

Wirelane – Saarbrücken (D)

Mobility services